2 * 10^6 + 2 * 10^8cells
Trade Name
Tecartus
Cell suspension for infusion
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:
• Mantle Cell Lymphoma
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Acute Lymphoblastic Leukemia
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
• Mantle Cell Lymphoma
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Acute Lymphoblastic Leukemia
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).